• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Oct. 1, 2013

View Archived Issues

U.S. Government is Too Big to Shut Down Completely

As the U.S. House and Senate continued their down-to-the-wire game of chicken Monday, government departments dusted off and updated their contingency plans in preparation for what threatened to be the first shutdown in nearly two decades should neither side give on a continuing resolution to fund federal programs after 12:01 a.m. (EDT) Tuesday, the dawn of fiscal 2014. Read More

Perjeta Approved for a New Treatment in HER2 Breast Cancer

Just a couple of weeks after the FDA’s Oncologic Drugs Advisory Committee voted overwhelmingly in favor of supporting approval of Genentech Inc.’s supplemental biologics license application (sBLA) for Perjeta (pertuzumab) in neoadjuvant treatment of breast cancer, the FDA granted accelerated approval of the drug. Read More

Hold the Liver: Achillion’s HCV Drug Still Stalled; Future Looks Dicey

As Achillion Pharmaceuticals Inc.’s stock reeled from the FDA’s refusal to lift the clinical hold imposed this summer on the hepatitis C virus (HCV) candidate sovaprevir because of elevated liver enzymes, analysts mulled the larger meaning and the company sought to reassure investors during a conference call. Read More

Relypsa Joins IPO Rush With a $126.5M Filing

Riding high on recent positive Phase III data for its hyperkalemia candidate, Relypsa Inc. filed for a $126.5 million initial public offering (IPO) to ramp up commercial operations for launch of patiromer, which is designed to remove potassium in the colon. Read More

MARQUEE Sign Shows Arqule’s Tivantinib Works in NSCLC Subset

Following disappointing results from Arqule Inc.’s Phase III study in non-small-cell lung cancer (NSCLC) a year ago, analysts had all but written off tivantinib in that indication. But detailed data reported at this week’s European Cancer Congress in Amsterdam suggested the oral MET inhibitor might have an opportunity in NSCLC after all. Read More

EU Grants Propel Procarta’s Work on New Antibiotics

LONDON – Procarta Biosystems Ltd. was awarded more than £1 million (US$1.6 million) in two European Union (EU) grants, enabling it to prepare the first of a new generation of antibiotics based on transcription factor decoys for the clinic, and providing a stepping stone to a funding round in which the company aims to raise £10 million. Read More

Lion Roars on Long-Term Metastatic Melanoma Data

Little Lion Biotechnologies Inc., the surviving entity of a merger earlier this year with Genesis Biopharma Inc., reported promising long-term findings from a Phase II trial in Stage IV metastatic melanoma. The study was conducted by the National Cancer Institute (NCI) using tumor-infiltrating lymphocyte (TIL) technology licensed by the company and in development under a five-year Cooperative Research and Development Agreement that Genesis inked with the Institute in 2011. Read More

Clinic Roundup

• Lithera Inc., of San Diego, reported positive results from its 513-patient Phase IIb RESET study of LIPO-202 (salmeterol xinafoate for Injection) designed to measure safety and efficacy of three different doses (0.4, 1 and 4 mcg [total dose]) in healthy, non-obese subjects with abdominal bulging due to excess subcutaneous fat. Read More

Stock Movers

Read More

Other News To Note

• Cardiome Pharma Corp., of Vancouver, British Columbia, said that the Medicines Control Council of South Africa approved Brinavess (vernakalant intravenous) for atrial fibrillation. Read More

ECC Roundup

• Exelixis Inc., of South San Francisco, provided updated results from BRIM7, an ongoing Phase Ib trial conducted by Roche AG and Genentech, Exelixis’ collaborator and part of Roche, of Basel, Switzerland, the BRAF inhibitor (BRAFi) vemurafenib in combination with the MEK inhibitor cobimetinib (GDC-0973/XL518) in patients with locally advanced/unresectable or metastatic melanoma carrying a BRAFV600 mutation. Read More

Pharma: Other News To Note

• Vansen Pharma Inc., of Montreal, said that its shares will trade under a new ticker symbol, VNSN, beginning Oct. 1. It previously changed its name from Okana Ventures Inc. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 11, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 11, 2025.
  • Enflonsia

    Merck wins FDA approval in pediatric RSV and steps into CDC uncertainty

    BioWorld
    With the U.S. FDA’s approval of Enflonsia (clesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...
  • AI-generated illustration of heart and metabolic impact

    Deep Apple signs big Novo deal for cardiometabolic small molecules

    BioWorld
    Deep Apple Therapeutics Inc. could bring in as much as $812 million in a new collaboration and license deal with Novo Nordisk A/S. The total includes an...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 10, 2025
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe